1h Free Analyst Time
The publisher has been monitoring the attention deficit hyperactivity disorder drugs market and it is poised to grow by $9.61 bn during 2021-2025, progressing at a CAGR of 9.06% during the forecast period. The report on the attention deficit hyperactivity disorder drugs market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.Speak directly to the analyst to clarify any post sales queries you may have.
The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by the rising government support and increasing expenditure on prescription drugs.
The attention deficit hyperactivity disorder drugs market analysis includes the product segment and geographic landscape.
The attention deficit hyperactivity disorder drugs market is segmented as below:
By Product
- Stimulants
- Non-stimulants
By Geographical Landscape
- North America
- Europe
- Asia
- ROW
This study identifies the rising prevalence of mental illnesses as one of the prime reasons driving the attention deficit hyperactivity disorder drugs market growth during the next few years.
The report on attention deficit hyperactivity disorder drugs market covers the following areas:
- Attention deficit hyperactivity disorder drugs market sizing
- Attention deficit hyperactivity disorder drugs market forecast
- Attention deficit hyperactivity disorder drugs market industry analysis
The publisher's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading attention deficit hyperactivity disorder drugs market vendors that include Aurobindo Pharma Ltd., Aytu BioPharma Inc., Eli Lilly and Co., Glenmark Pharmaceuticals Ltd., Johnson and Johnson Inc., Novartis AG, Purdue Pharma LP, SHIONOGI Co. Ltd., Takeda Pharmaceutical Co. Ltd., and Tris Pharma Inc. Also, the attention deficit hyperactivity disorder drugs market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.
Table of Contents
Executive Summary- Market Overview
Market Landscape
- Market ecosystem
- Value chain analysis
Market Sizing
- Market definition
- Market segment analysis
- Market size 2020
- Market outlook: Forecast for 2020 - 2025
Five Forces Analysis
- Bargaining power of buyers
- Bargaining power of suppliers
- Threat of new entrants
- Threat of substitutes
- Threat of rivalry
- Market condition
Market Segmentation by Product
- Market segments
- Comparison by Product
- Stimulants - Market size and forecast 2020-2025
- Non-stimulants - Market size and forecast 2020-2025
- Market opportunity by Product
Customer landscape
Geographic Landscape
- Geographic segmentation
- Geographic comparison
- North America - Market size and forecast 2020-2025
- Europe - Market size and forecast 2020-2025
- Asia - Market size and forecast 2020-2025
- ROW - Market size and forecast 2020-2025
- Key leading countries
- Market opportunity By Geographical Landscape
- Market drivers
- Market challenges
- Market trends
Vendor Landscape
- Landscape disruption
Vendor Analysis
- Vendors covered
- Market positioning of vendors
- Aurobindo Pharma Ltd.
- Aytu BioPharma Inc.
- Eli Lilly and Co.
- Glenmark Pharmaceuticals Ltd.
- Johnson and Johnson Inc.
- Novartis AG
- Purdue Pharma LP
- SHIONOGI Co. Ltd.
- Takeda Pharmaceutical Co. Ltd.
- Tris Pharma Inc.
Appendix
- Scope of the report
- Currency conversion rates for US$
- Research methodology
- List of abbreviations
List of Exhibits
- Key Finding 1
- Key Finding 2
- Key Finding 3
- Key Finding 5
- Key Finding 6
- Key Finding 7
- Key Finding 8
- Parent market
- Market characteristics
- Offerings of vendors included in the market definition
- Market segments
- Global - Market size and forecast 2020 - 2025 ($ million)
- Global market: Year-over-year growth 2020 - 2025 (%)
- Five forces analysis 2020 & 2025
- Bargaining power of buyers
- Bargaining power of suppliers
- Threat of new entrants
- Threat of substitutes
- Threat of rivalry
- Market condition - Five forces 2020
- Product - Market share 2020-2025 (%)
- Comparison by Product
- Stimulants - Market size and forecast 2020-2025 ($ million)
- Stimulants - Year-over-year growth 2020-2025 (%)
- Non-stimulants - Market size and forecast 2020-2025 ($ million)
- Non-stimulants - Year-over-year growth 2020-2025 (%)
- Market opportunity by Product
- Customer landscape
- Market share By Geographical Landscape 2020-2025 (%)
- Geographic comparison
- North America - Market size and forecast 2020-2025 ($ million)
- North America - Year-over-year growth 2020-2025 (%)
- Europe - Market size and forecast 2020-2025 ($ million)
- Europe - Year-over-year growth 2020-2025 (%)
- Asia - Market size and forecast 2020-2025 ($ million)
- Asia - Year-over-year growth 2020-2025 (%)
- ROW - Market size and forecast 2020-2025 ($ million)
- ROW - Year-over-year growth 2020-2025 (%)
- Key leading countries
- Market opportunity By Geographical Landscape ($ million)
- Impact of drivers and challenges
- Vendor landscape
- Landscape disruption
- Industry risks
- Vendors covered
- Market positioning of vendors
- Aurobindo Pharma Ltd. - Overview
- Aurobindo Pharma Ltd. - Product and service
- Aurobindo Pharma Ltd. - Key offerings
- Aurobindo Pharma Ltd. - Key customers
- Aurobindo Pharma Ltd. - Segment focus
- Aytu BioPharma Inc. - Overview
- Aytu BioPharma Inc. - Product and service
- Aytu BioPharma Inc. - Key offerings
- Aytu BioPharma Inc. - Key customers
- Aytu BioPharma Inc. - Segment focus
- Eli Lilly and Co. - Overview
- Eli Lilly and Co. - Business segments
- Eli Lilly and Co. - Key offerings
- Eli Lilly and Co. - Key customers
- Eli Lilly and Co. - Segment focus
- Glenmark Pharmaceuticals Ltd. - Overview
- Glenmark Pharmaceuticals Ltd. - Business segments
- Glenmark Pharmaceuticals Ltd. - Key offerings
- Glenmark Pharmaceuticals Ltd. - Key customers
- Glenmark Pharmaceuticals Ltd. - Segment focus
- Johnson and Johnson Inc. - Overview
- Johnson and Johnson Inc. - Business segments
- Johnson and Johnson Inc. - Key offerings
- Johnson and Johnson Inc. - Key customers
- Johnson and Johnson Inc. - Segment focus
- Novartis AG - Overview
- Novartis AG - Business segments
- Novartis AG - Key offerings
- Novartis AG - Key customers
- Novartis AG - Segment focus
- Purdue Pharma LP - Overview
- Purdue Pharma LP - Product and service
- Purdue Pharma LP - Key offerings
- Purdue Pharma LP - Key customers
- Purdue Pharma LP - Segment focus
- SHIONOGI Co. Ltd. - Overview
- SHIONOGI Co. Ltd. - Business segments
- SHIONOGI Co. Ltd. - Key offerings
- SHIONOGI Co. Ltd. - Key customers
- SHIONOGI Co. Ltd. - Segment focus
- Takeda Pharmaceutical Co. Ltd. - Overview
- Takeda Pharmaceutical Co. Ltd. - Product and service
- Takeda Pharmaceutical Co. Ltd. - Key offerings
- Takeda Pharmaceutical Co. Ltd. - Key customers
- Takeda Pharmaceutical Co. Ltd. - Segment focus
- Tris Pharma Inc. - Overview
- Tris Pharma Inc. - Product and service
- Tris Pharma Inc. - Key offerings
- Tris Pharma Inc. - Key customers
- Tris Pharma Inc. - Segment focus
- Currency conversion rates for US$
- Research Methodology
- Validation techniques employed for market sizing
- Information sources
- List of abbreviations
Executive Summary
The publisher recognizes the following companies as the key players in the global attention deficit hyperactivity disorder drugs market: Aurobindo Pharma Ltd., Aytu BioPharma Inc., Eli Lilly and Co., Glenmark Pharmaceuticals Ltd., Johnson and Johnson Inc., Novartis AG, Purdue Pharma LP, SHIONOGI Co. Ltd., Takeda Pharmaceutical Co. Ltd., and Tris Pharma Inc.Commenting on the report, an analyst from the research team said: 'The latest trend gaining momentum in the market is rising prevalence of mental illnesses.'
According to the report, one of the major drivers for this market is the rising government support.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Aurobindo Pharma Ltd.
- Aytu BioPharma Inc.
- Eli Lilly and Co.
- Glenmark Pharmaceuticals Ltd.
- Johnson and Johnson Inc.
- Novartis AG
- Purdue Pharma LP
- SHIONOGI Co. Ltd.
- Takeda Pharmaceutical Co. Ltd.
- Tris Pharma Inc.
